Global Vitreoretinal Surgery Devices Market By Product (Vitrectomy Machines and Combined Surgical Platforms, Vitrectomy Cutters and Probes, Trocar-Cannula Systems, Illumination Devices, Retinal Laser Systems and Endolaser Probes, Vitreoretinal Forceps, Scissors, and Other Instruments, Surgical Fluids and Dyes, Gas and Silicone Oil Tamponades, Procedure Packs, Tubing Sets, and Other Consumables); By Application (Retinal Detachment, Diabetic Retinopathy Complications, Vitreous Hemorrhage, Macular Hole, Epiretinal Membrane, Ocular Trauma, Endophthalmitis, Pediatric Retinal Disorders, Other Vitreoretinal Conditions); By End User (Hospitals, Ambulatory Surgical Centers, Specialty Ophthalmology Clinics, Academic and Research Institutions); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation and Forecast, 2026–2032

Vitreoretinal Surgery Devices Market: Procedure Growth, Recurring Consumables, and Platform Replacement Drive Revenue

The Global Vitreoretinal Surgery Devices Market is projected to grow from USD 2.76 billion in 2025 to USD 4.74 billion by 2032, registering a healthy CAGR of 7.9%, according to Strategic Market Research.

 

U.S. Medicare data show that pars plana vitrectomy-associated services increased from 71,039 in 2000 to 95,429 in 2021, representing an annualized growth rate of approximately 1.4%. Vitrectomy-based retinal-detachment repairs rose from 14,984 to 22,299 during the same period, equivalent to an annualized increase of about 1.9%. These trends indicate a sustained movement toward procedures that consume vitrectomy platforms and related disposables.

 

Alcon estimated that approximately 2.2 million vitrectomy procedures were performed globally in 2024. This worldwide procedure base supports recurring demand for vitrectomy probes, cannulas, illumination products, surgical instruments, fluids, and tamponades.

 

Vitrectomy Gains Ground in Retinal-Detachment Repair

Retinal detachment creates one of the market’s most immediate surgical demand channels because treatment delays can increase the risk of permanent vision loss. Surgeons may use pars plana vitrectomy, scleral buckling, pneumatic retinopexy, or a combined approach, depending on the location and complexity of the detachment.

Procedure patterns increasingly favor vitrectomy. Medicare recorded 22,299 vitrectomy-based retinal-detachment repairs in 2021, compared with 587 stand-alone scleral-buckle procedures and 2,225 pneumatic retinopexies. Within these three reported retinal-detachment service categories, vitrectomy-based repair represented approximately 88.8% of the volume, compared with 8.9% for pneumatic retinopexy and 2.3% for stand-alone scleral buckling. This procedure-mix share strengthens demand for vitrectomy consoles and the consumable systems used to access the eye, remove vitreous, stabilize the retina, apply laser treatment, and place an internal tamponade.

England recorded a similar shift. Pars plana vitrectomy procedures increased from 5,761 in 2000 to 26,900 in 2018, representing annualized growth of approximately 8.9%. Hospital admissions for retinal detachment with breaks rose from 3,447 to 10,971, while scleral-buckling procedures declined from 2,897 to 780 over the same period. Aging populations, higher myopia prevalence, previous cataract surgery, wider surgical access, and growing surgeon familiarity with vitrectomy have contributed to this change.

The procedure shift has a direct commercial effect. Each vitrectomy can create demand for cutters, trocar-cannula sets, infusion lines, illumination products, endolaser probes, forceps, surgical fluids, and gas or silicone-oil tamponades. Manufacturers offering these products as a connected portfolio can increase revenue per case and strengthen customer retention.

 

Diabetic Retinal Disease Builds a Large Surgical Referral Pool

Diabetic retinopathy represents the largest underlying disease population associated with vitreoretinal surgery. The U.S. Centers for Disease Control and Prevention estimated that 9.60 million people were living with diabetic retinopathy in 2021, including approximately 1.84 million with vision-threatening disease. Vision-threatening cases therefore accounted for about 19.1% of the U.S. diabetic-retinopathy population and included proliferative diabetic retinopathy, severe non-proliferative disease, and diabetic macular edema.

Globally, an epidemiological analysis estimated that 103.12 million adults had diabetic retinopathy in 2020, including 28.54 million with vision-threatening disease. This severe group represented approximately 27.7% of the global diabetic-retinopathy population. The respective populations were projected to reach 160.50 million and 44.82 million by 2045, expanding the pool of patients who may eventually require advanced medical or surgical intervention.

Most patients are managed through screening, glucose control, anti-vascular endothelial growth factor injections, observation, or retinal laser treatment. Surgery becomes necessary when patients develop non-clearing vitreous hemorrhage, tractional retinal detachment, fibrous membrane formation, or other advanced complications that cannot be controlled through earlier treatment.

Medicare intravitreal-injection services increased from 2,922 in 2000 to more than 3.44 million in 2021. Panretinal photocoagulation services declined from 104,865 to 48,533 during the same period as injections became more prominent in retinal care. Although medical treatments can delay some complications, they do not eliminate surgical demand among patients with advanced hemorrhage, traction, detachment, or treatment-resistant disease.

The market opportunity is therefore concentrated in severe disease rather than the entire diabetic-retinopathy population. Complex diabetic cases also tend to require a wider collection of surgical instruments and consumables, including membrane-peeling tools, fluid-management products, endolaser probes, and tamponades.

 

Macular Surgery Adds Planned Procedure Demand

Macular holes and epiretinal membranes contribute a smaller but commercially valuable stream of scheduled vitreoretinal procedures. Many patients are monitored until visual distortion, reduced acuity, or disease progression justifies surgery.

Once intervention is selected, macular procedures commonly require small-gauge access systems, vitrectomy cutters, staining dyes, membrane-peeling forceps, illumination, fluid-air exchange, and gas tamponade. This creates a high level of consumable use per operation despite the smaller patient population.

These surgeries are generally more predictable than emergency retinal-detachment procedures. Hospitals and ambulatory surgical centers can schedule operating-room capacity, prepare standardized procedure packs, and manage instrument inventory in advance. Suppliers that provide integrated macular-surgery packs and compatible instruments can benefit from this repeatable purchasing pattern.

 

Consumables Create the Market’s Recurring Revenue Base

Vitrectomy platforms represent high-value capital purchases, but procedure-linked products generate the market’s most consistent revenue. A console may support thousands of operations during its installed life, while cutters, cannulas, tubing, laser probes, dyes, fluids, and procedure packs must be replenished for individual cases.

Platform compatibility strengthens this recurring model. Hospitals that standardize around one console often purchase related probes, packs, instruments, and fluid-management products from the same supplier. Changing platforms can require staff retraining, inventory replacement, service adjustments, and modifications to surgical routines.

Alcon’s 2025 results demonstrate the commercial weight of consumables across a major ophthalmic surgical portfolio. The company generated USD 5.75 billion in surgical sales, equal to approximately 55.7% of its USD 10.32 billion in total net sales. Surgical consumables contributed USD 3.03 billion, representing about 52.7% of the surgical segment, while equipment and other sales contributed USD 941 million, or 16.4%. Implantables represented the remaining 31.0%, with revenue of USD 1.78 billion.

Alcon’s surgical consumables revenue increased 6% in 2025, supported by vitreoretinal procedure growth and pricing. Equipment and other sales also grew 6% for the full year as the newly launched UNITY platform offset declines in older equipment. Fourth-quarter equipment revenue increased 21% to USD 277 million, showing how a platform launch can temporarily accelerate capital sales while creating a larger base for future disposable purchases.

Specialized companies can establish positions within selected procedural categories. IRIDEX participates through retinal laser systems and sterile disposable EndoProbe handpieces. This model creates recurring probe sales without requiring the company to compete across the complete vitrectomy platform.

 

Platform Replacement Opens a New Capital-Spending Cycle

Manufacturers are introducing new surgical systems as hospitals evaluate replacements for aging vitrectomy consoles. Purchasing decisions increasingly consider operating-room productivity, equipment reliability, service coverage, inventory requirements, surgeon preference, and the ability to perform both anterior- and posterior-segment procedures on one platform.

Alcon received U.S. FDA 510(k) clearance for the UNITY Vitreoretinal Cataract System in June 2024. The system supports cataract and vitreoretinal procedures, including vitrectomy, illumination, fluid management, diathermy, tissue manipulation, and optional laser photocoagulation. Commercial shipments began in 2025 after approvals across major ophthalmic markets.

Alcon has stated that more than 28,000 CENTURION cataract and CONSTELLATION vitreoretinal systems were installed across the market and could represent upgrade opportunities for the UNITY portfolio over the following decade. The replacement cycle gives Alcon an opportunity to migrate existing users to newer equipment while securing future consumable and service revenue.

The early sales effect became visible in 2025. Alcon’s equipment and other revenue reached USD 941 million for the year, up 6%, while fourth-quarter growth reached 21% as UNITY adoption accelerated. Equipment represented 16.4% of the company’s surgical sales, compared with the 52.7% share generated by consumables, illustrating how capital placement can support a much larger recurring product business.

Oertli has introduced the OS 4 Up platform for cataract and vitreoretinal surgery alongside the Caliburn Trocar System and Continuous Flow Cutter. Its launch gives hospitals another combined-platform option and increases competition around equipment cost, service, consumable compatibility, and surgical workflow.

 

Competition Shifts Toward Connected Surgical Portfolios

Alcon competes through CONSTELLATION, UNITY VCS, vitrectomy probes, cannulas, laser products, illumination, forceps, visualization technologies, procedure packs, and a large service network. Its USD 5.75 billion surgical business grew 4% in 2025, while consumables and equipment each expanded 6%, strengthening its ability to compete through both installed systems and recurring products.

Carl Zeiss Meditec completed its acquisition of Dutch Ophthalmic Research Center in April 2024. DORC added the EVA NEXUS platform, vitreoretinal instruments, trocar systems, cutters, liquids, tamponades, and consumables to ZEISS’s portfolio of diagnostic imaging, surgical microscopes, visualization, and digital workflow products.

ZEISS’s Ophthalmology Strategic Business Unit generated EUR 1.72 billion in fiscal 2024/25, an increase of 8.5% from EUR 1.59 billion. Ophthalmology represented approximately 77.4% of the group’s EUR 2.23 billion revenue, with the full-year consolidation of DORC contributing to growth. Revenue expanded 9.3% on a currency-adjusted basis and 2.3% after currency and acquisition effects, indicating that the acquisition and the existing business both contributed to the result.

DORC also increased the role of recurring products within ZEISS. Consumables, implants, and services represented 47% of Carl Zeiss Meditec’s revenue in fiscal 2023/24, up from 43% in the previous year, with the DORC acquisition identified as a major contributor. This revenue mix supports ZEISS’s movement from equipment-led sales toward procedure-linked income.

Bausch + Lomb participates through the Stellaris Elite platform, Bi-Blade and single-port cutters, illumination products, laser probes, and posterior-segment accessories. Oertli competes through the OS 4 Up platform, trocar systems, cutters, instruments, and sterile consumables, while IRIDEX holds a focused position in retinal laser systems and disposable endolaser probes.

Competitive advantage increasingly depends on the installed platform, availability of compatible disposables, surgeon familiarity, local training, maintenance response, financing, distributor reach, and the supplier’s ability to secure multi-product contracts.

 

Regional Market Direction

North America remains a major revenue market because of its large diagnosed retinal-disease population, specialist retina networks, Medicare coverage, ambulatory surgical infrastructure, and early adoption of newly cleared systems. The United States combines strong procedure demand with reimbursement pressure, making service reliability and per-procedure economics central to purchasing.

Europe has a mature surgical base and includes important manufacturers such as ZEISS/DORC and Oertli. England’s approximately 8.9% annualized growth in pars plana vitrectomy procedures between 2000 and 2018 illustrates the long-term expansion of surgical activity. Demand varies across national hospital budgets, tender systems, reimbursement structures, and specialist availability.

Asia-Pacific offers strong long-term potential because of its large diabetic population, aging demographics, growing urban eye-care networks, and expanding hospital investment. ZEISS generated EUR 991 million from Asia-Pacific in fiscal 2024/25, equivalent to approximately 44.5% of company revenue, compared with EUR 658 million or 29.5% from Europe, the Middle East and Africa and EUR 579 million or 26.0% from the Americas. The company’s Asia-Pacific revenue grew 4.4%, while EMEA and the Americas expanded 12.5% and 8.7%, respectively.

 

Market Outlook

The vitreoretinal surgery devices market will expand at a CAGR of 7.9% through higher vitrectomy utilization, growth in advanced diabetic retinal disease, scheduled macular procedures, repeat operations, and replacement of older surgical systems.

Consumables will remain the most dependable revenue stream because every operation can generate purchases across cutters, cannulas, probes, packs, fluids, dyes, and tamponades. Alcon’s consumables business already represents more than half of its surgical revenue, while ZEISS has increased its recurring-revenue exposure through DORC.

Alcon’s UNITY rollout, ZEISS’s integration of DORC, and Oertli’s OS 4 Up launch signal stronger competition around combined platforms and connected surgical workflows. Suppliers that combine reliable equipment, predictable disposable costs, responsive service, clinical training, and broad procedural portfolios will be best positioned to gain hospital and ambulatory surgical center contracts through 2032.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.76 Billion
Revenue Forecast in 2032	USD 4.74 Billion
Overall Growth Rate	CAGR of 7.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product, By Application, By End User, By Geography
By Product	Vitrectomy Machines and Combined Surgical Platforms, Vitrectomy Cutters and Probes, Trocar-Cannula Systems, Illumination Devices, Retinal Laser Systems and Endolaser Probes, Vitreoretinal Forceps, Scissors, and Other Instruments, Surgical Fluids and Dyes, Gas and Silicone Oil Tamponades, Procedure Packs, Tubing Sets, and Other Consumables
By Application	Retinal Detachment, Diabetic Retinopathy Complications, Vitreous Hemorrhage, Macular Hole, Epiretinal Membrane, Ocular Trauma, Endophthalmitis, Pediatric Retinal Disorders, Other Vitreoretinal Conditions
By End User	Hospitals, Ambulatory Surgical Centers, Specialty Ophthalmology Clinics, Academic and Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising incidence of retinal detachment and diabetic retinal complications, increasing adoption of minimally invasive micro-incision vitrectomy procedures, growing demand for integrated surgical visualization and laser platforms, expansion of ophthalmic surgical capacity across ambulatory and specialty-care settings
Customization Option	Available upon request